Back to top
more

Amgen (AMGN)

(Real Time Quote from BATS)

$301.56 USD

301.56
154,808

+0.86 (0.29%)

Updated Jun 12, 2024 10:30 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva

Amgen (AMGN) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Amgen (AMGN) closed at $234.01 in the latest trading session, marking a +0.07% move from the prior day.

Biotech Stock Roundup: ASH Data in Focus, Amgen Gets FDA Nod to Remicade Biosimilar

by Zacks Equity Research

The biotech sector witnesses pipeline updates from the annual ASH meet.

Sweta Killa headshot

Biotech ETFs Hit New Highs on Deal Activities

by Sweta Killa

Following the new deals in the healthcare space, a few biotech ETFs hit new highs.

Healthpeak Amends & Extends Lease With Amgen in San Francisco

by Zacks Equity Research

Healthpeak's (PEAK) lease amendment and extension with Amgen at the Britannia Oyster Point of the former offers flexibility in addressing lease-expiration issue at this property.

Amgen Gets FDA Approval for J&J/Merck's Remicade Biosimilar

by Zacks Equity Research

FDA gives nod to Amgen's (AMGN) Avsola (ABP 710), a biosimilar of J&J's blockbuster rheumatoid arthritis drug, Remicade.

Biogen Up on New Data on Alzheimer's Candidate Aducanumab

by Zacks Equity Research

Biogen (BIIB) divulges new positive data on Alzheimer's candidate, aducanumab at CTAD. Stock rises.

Biogen's Shares Down on Rating Downgrade by Baird Analyst

by Zacks Equity Research

Biogen's (BIIB) shares decline following a rating downgrade by an analyst at Robert W. Baird on concerns related to approval of Alzheimer's disease candidate, aducanumab.

Merck's Keytruda Gets FDA's Priority Tag in Bladder Cancer

by Zacks Equity Research

Merck's (MRK) sBLA for Keytruda gets FDA's priority review status to treat certain patients with high-risk, non-muscle invasive bladder cancer.

The Zacks Analyst Blog Highlights: Intercept, CymaBay, Amgen, Global Blood Therapeutics and ChemoCentryx

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Intercept, CymaBay, Amgen, Global Blood Therapeutics and ChemoCentryx

Amgen (AMGN) Up 11.2% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why Merck's (MRK) Shares Are Up This Year

by Zacks Equity Research

Merck's (MRK) shares are up 11.7% this year so far on strong performance and positive regulatory updates on its PD-1 inhibitor Keytruda.

Merck's Keytruda Gets Nod in China for Difficult Lung Cancer

by Zacks Equity Research

Merck (MRK) receives the third approval of Keytruda for first-line non-small cell lung cancer patient population in China.

Biotech Stock Roundup: CBAY Falls, CCXI Gains, Amgen Acquires Otezla & More

by Zacks Equity Research

Key highlights of the past week include regulatory and pipeline updates.

Novartis (NVS) to Acquire The Medicines Company for $9.7B

by Zacks Equity Research

Novartis (NVS) set to acquire The Medicines Company and add a promising candidate to its cardiovascular pipeline.

The Medicines Company to be Acquired by Novartis for $9.7B

by Zacks Equity Research

The Medicines Company (MDCO) agrees to the $85 per share or $9.7-billion acquisition offer from Novartis.

The Zacks Analyst Blog Highlights: Facebook, Bank of America, Home Depot, Amgen and Intuitive

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Facebook, Bank of America, Home Depot, Amgen and Intuitive

Amgen (AMGN) Completes Otezla Buyout, Raises 2019 Guidance

by Zacks Equity Research

Amgen (AMGN) concludes the pending buyout of Celgene's psoriasis drug Otezla to acquire its worldwide rights. The company also hikes its overall 2019 view. Stock gains.

Bristol-Myers' Melanoma Study Misses Goal, Closes Celgene Deal

by Zacks Equity Research

Bristol-Myers' (BMY) late-stage study evaluating the Opdivo-Yervoy combo fails to meet a co-primary endpoint of recurrence-free survival in melanoma patients. The company wraps up Celgene acquisition.

Merck's Keytruda Wins EU Nod for First-Line Head/Neck Cancer

by Zacks Equity Research

Merck's (MRK) Keytruda gets approval in Europe to treat first-line head/neck cancer based on data from the phase III KEYNOTE-048 study.

Mark Vickery headshot

Top Stock Reports for Facebook, Bank of America & Home Depot

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Facebook (FB), Bank of America (BAC) and Home Depot (HD).

Merck's Heart Failure Candidate Meets Goal in Phase III Study

by Zacks Equity Research

Merck (MRK) and German partner Bayer's vericiguat reduces the risk of heart failure hospitalization or cardiovascular death in patients with worsening chronic heart failure.

Pfizer Gets FDA Approval for Biosimilar of AbbVie's Humira

by Zacks Equity Research

The approval of Humira biosimilar is the fourth U.S. approval of a biosimilar product for Pfizer (PFE) in 2019.

4 Big Biotech Stocks Worth Considering Post Q3 Earnings

by Zacks Equity Research

We highlight a few principal players from the biotech sector, which are likely to witness a winning run in the near term.

Bristol-Myers Gets FTC Clearance for Celgene Acquisition

by Zacks Equity Research

Bristol-Myers (BMY) obtains FTC permission for the Celgene acquisition and will divest Otezla to Amgen.

Amarin (AMRN) Gets FDA Panel Nod for Vascepa Label Expansion

by Zacks Equity Research

Amarin (AMRN) gets favorable FDA Advisory Committee vote to expand the label of Vascepa capsules to reduce cardiovascular risk in patients with persistent elevated triglycerides.